ArticleTheranostics2017
Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy.
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- EngineeredMolecular therapy. Oncology · 2026Article
- Innovative biomaterial solutions for enhancing the efficacy of tumor immunotherapy.Immunologic research · 2026Review
- Polydopamine Nanocomposite Hydrogel for Drug Slow-Release in Bone Defect Repair: A Review of Research Advances.Gels (Basel, Switzerland) · 2025Review
- Targeting Delivery of Dexamethasone to Inflamed Joints by Albumin-Binding Peptide Modified Liposomes for Rheumatoid Arthritis Therapy.International journal of nanomedicine · 2025Article
- Synthetic organic materials for targeting immunotherapies to lymph nodes.Chemistry of materials : a publication of the American Chemical Society · 2024Article
- Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development.Pharmaceutics · 2024Review
- Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer.Frontiers in immunology · 2023Review
- Nanomaterial-Based Drug Delivery System Targeting Lymph Nodes.Pharmaceutics · 2022Review
- The Landscape of Nanovectors for Modulation in Cancer Immunotherapy.Pharmaceutics · 2022Review
- Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects.Theranostics · 2022Review
- Recent Advance of Nanomaterial-Mediated Tumor Therapies in the Past Five Years.Frontiers in pharmacology · 2022Review
- Stimuli-Responsive Polymeric Nanomaterials for the Delivery of Immunotherapy Moieties: Antigens, Adjuvants and Agonists.International journal of molecular sciences · 2021Review
- Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8Biomaterials · 2021Article
- Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review).Experimental and therapeutic medicine · 2021Review
- Polymeric Micelles in Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2021Review
- Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy.Frontiers in immunology · 2021Review
- Polymeric nanoparticle vaccines to combat emerging and pandemic threats.Biomaterials · 2021Review
- Surface-decorated nanoparticles clicked into nanoparticle clusters for oligonucleotide encapsulation.RSC advances · 2020Article
- Advanced biomaterials for cancer immunotherapy.Acta pharmacologica Sinica · 2020Review
- Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy.Acta pharmacologica Sinica · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poor distribution of antigen/adjuvant to target sites and inadequate induction of T cell responses remain major challenges in cancer immunotherapy because of the lack of appropriate delivery systems. Nanocarrier-based antigen delivery systems have emerged as an innovative strategy to improve vaccine efficacy. Here we present polymeric hybrid micelles (PHMs) as a simple and potent antigen/adjuvant co-delivery system with highly tunable properties. PHMs consist of two amphiphilic diblock copolymers, polycaprolactone-polyethylenimine (PCL-PEI) and polycaprolactone-polyethyleneglycol (PCL-PEG). PHMs with different proportions of cationic PCL-PEI were prepared and loaded with tyrosinase-related protein 2 (Trp2) peptide and adjuvant CpG oligodeoxynucleotide to generate the Trp2/PHM/CpG co-delivery system. Lymphatic and intracellular antigen delivery as a function of PCL-PEI proportion was evaluated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.